UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000007539 |
|---|---|
| Receipt number | R000008853 |
| Scientific Title | Follow-up study of patients with rheumatoid arthritis who treated infliximab for 1 year and did not reach a clinical remission in RRRR Study |
| Date of disclosure of the study information | 2012/04/01 |
| Last modified on | 2017/09/25 09:16:06 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Follow-up study of patients with rheumatoid arthritis who treated infliximab for 1 year and did not reach a clinical remission in RRRR Study
Acronym
Remission induction by Raising the dose of Remicade in RA Extension study (RRRR-EX Study)
Scientific Title
Follow-up study of patients with rheumatoid arthritis who treated infliximab for 1 year and did not reach a clinical remission in RRRR Study
Scientific Title:Acronym
Remission induction by Raising the dose of Remicade in RA Extension study (RRRR-EX Study)
Region
| Japan |
Condition
Condition
Rheumatoid Arthritis
Classification by specialty
| Endocrinology and Metabolism | Clinical immunology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Evaluate clinical remission in patients who continue treatment with IFX administration after failing to reach a clinical remission at 1 year treatment with IFX in RRRR Study
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Not applicable
Assessment
Primary outcomes
Proportion of clinical remission 1 year after enrolling in RRRR-RX Study
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 18 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1)Patients who did not reach a clinical remission at the time of 54 weeks from first administration of IFX in RRRR Study
2)Patients who continue treatment with IFX administration after failing to reach a clinical remission
3)Written informed consent
Key exclusion criteria
1)Patients who discontinued IFX treatment prior to 54 week from the first administration of IFX in the RRRR Study
2) Patients who are inadequate to enter this trial due to the other reasons by physician's judgments
Target sample size
108
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Yoshiya Tanaka |
Organization
University of Occupational and Environmental Health, Japan
Division name
The First Department of Internal Medicine, School of Medicine
Zip code
Address
1-1, Iseigaoka, Yahata-nishi-ku, Kitakyushu, Japan
TEL
093-603-1611
tanaka@med.uoeh-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Nao Horie |
Organization
Hokkaido University Hospital
Division name
Translational Research and Clinical Trial Center
Zip code
Address
Nishi-5, Kita-14, Kita-ku, Sapporo, Hokkaido, Japan
TEL
011-706-7735
Homepage URL
RRRR@pop.med.hokudai.ac.jp
Sponsor or person
Institute
University of Occupational and Environmental Health, Japan
Institute
Department
Personal name
Funding Source
Organization
A Research Grant-In-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan (partly), Self funding
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
産業医科大学(福岡県)
医療法人早石会早石病院(大阪府)
東京医科歯科大学(東京都)
長崎大学病院(長崎県)
東北大学病院(宮城県)
埼玉医科大学総合医療センター(埼玉県)
医療法人社団善仁会市民の森病院(宮崎県)
埼玉医科大学(埼玉県)
香川大学医学部(香川県)
財団法人天理よろづ相談所病院(奈良県)
横浜市立みなと赤十字病院(神奈川県)
青森県立中央病院(青森県)
名古屋大学医学部(愛知県)
牛尾整形外科(大阪府)
北海道大学病院(北海道)
久留米大学医療センター(福岡県)
順天堂大学医学部(東京都)
慶應義塾大学医学部(東京都)
京都大学医学部附属病院京都府)
松原メイフラワー病院(兵庫県)
医療法人社団順和会 京都下鴨病院(京都府)
日本赤十字社大阪赤十字病院(大阪府)
医療法人財団白十字会 佐世保中央病院(長崎県)
兵庫医科大学(兵庫県)
北里大学病院(東京都)
医療法人社団 協志会宇多津浜クリニック(香川県)
関西医科大学附属枚方病院(大阪府)
日本赤十字社松山赤十字病院(愛媛県)
Other administrative information
Date of disclosure of the study information
| 2012 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2012 | Year | 03 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2012 | Year | 04 | Month | 01 | Day |
Last follow-up date
| 2015 | Year | 11 | Month | 30 | Day |
Date of closure to data entry
| 2017 | Year | 10 | Month | 31 | Day |
Date trial data considered complete
| 2017 | Year | 11 | Month | 30 | Day |
Date analysis concluded
| 2018 | Year | 06 | Month | 30 | Day |
Other
Other related information
prospective observational study
Management information
Registered date
| 2012 | Year | 03 | Month | 21 | Day |
Last modified on
| 2017 | Year | 09 | Month | 25 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008853
